Mab A Case Study In Bioprocess Development: A

This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety.

Fractogel EMD TMAE.

Continuous processing offers transformative benefits. By linking upstream perfusion bioreactors directly to downstream multi-column chromatography (MCC), the entire manufacturing process runs uninterrupted. This leads to a more homogeneous product, significantly reduced equipment footprint (70% smaller, by some estimates), and dramatic cost reductions. Continuous processing can achieve up to 35% cost savings compared to batch methods for annual productions of 100–500 kg. Companies like Enzene, with their FCCM™ platform, have already achieved mAb production costs of less than $40 per gram, a fraction of the $150-300 per gram typical of fed-batch processes.

A humanized IgG1 monoclonal antibody (mAb) targeting the immune checkpoint protein PD-L1, indicated for solid tumors. Challenge: The original lead candidate, produced in murine ascites, had low productivity (0.2 g/L) and high immunogenicity risk. The goal: develop a scalable, GMP-compliant process for Phase I clinical trials with a target titer >3 g/L and ≥95% purity.

Scale-up from 250 mL shake flasks to 15L glass bioreactors, and eventually to a 500L single-use bioreactor (SUB), was executed using constant oxygen mass transfer coefficient ( kLak sub cap L a ) and constant tip speed scaling strategies. Maintaining a kLak sub cap L a of approximately prevented carbon dioxide accumulation (

The primary goal of upstream development is to maximize volumetric productivity while ensuring the critical quality attributes (CQAs) of the mAb remain within predefined limits. Cell Line Development

Centrifugation followed by depth filtration was implemented to remove cells and debris. The clarification process was optimized to maintain low turbidity, reducing the load on subsequent chromatography steps. 3.2. Capture Step: Protein A Affinity Chromatography

The low pH eluate from the Protein A column was held at pH 3.5 for 60 minutes at 20°C to inactivate enveloped viruses. Following the hold, the solution was neutralized to pH 5.5 using Tris buffer, causing minor precipitation of impurities which were removed via a 0.22 µm depth filter. Polishing Chromatography

To ensure safety, the eluate undergoes low-pH viral inactivation (pH 3.6 for 90 minutes). For Mab-X, which is moderately acid-labile, the team adds 100 mM sodium acetate as a stabilizing excipient during this step. Post-inactivation, pH is raised to 5.5 using 2M Tris base. Analytical data confirm >4 log reduction of model viruses (xMuLV) without compromising product quality.